ZC0109
Based on 1 Customer Validation
ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC50s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.
For research use only. We do not sell to patients.
- Purity : 99.86%
- CAS No.: 3037850-79-3
- Formula: C22H20BrFN8O4S
- Molecular Weight:591.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
IC50: 50 nM (IDO1), 3.0 μM (TrxR1)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CT26 | IC50 |
12.4 μM
Compound: 12d; ZC0109
|
Cytotoxicity against mouse CT26 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against mouse CT26 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 36370550] |
| HCT-116 | IC50 |
1.52 μM
Compound: 12d; ZC0109
|
Cytotoxicity against TrxR1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 3.08 +/- 0.55 uM)
Cytotoxicity against TrxR1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 3.08 +/- 0.55 uM)
|
[PMID: 36370550] |
| HCT-116 | IC50 |
1.67 nM
Compound: 12d; ZC0109
|
Cytotoxicity against human HCT-116 cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)
Cytotoxicity against human HCT-116 cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)
|
[PMID: 36370550] |
| HCT-116 | IC50 |
18.08 nM
Compound: 12d; ZC0109
|
Cytotoxicity against IDO1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 36.50 +/- 3.20 nM)
Cytotoxicity against IDO1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 36.50 +/- 3.20 nM)
|
[PMID: 36370550] |
| HCT-116 | IC50 |
3.33 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HCT-116 cells incubated for 24 hrs CCK-8 assay
Cytotoxicity against human HCT-116 cells incubated for 24 hrs CCK-8 assay
|
[PMID: 36370550] |
| HCT-116 | IC50 |
3.44 μM
Compound: 12d; ZC0109
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay
|
[PMID: 36370550] |
| HCT-116 | IC50 |
3.44 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 36370550] |
| HCT-116 | IC50 |
3.79 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HCT-116 cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)
Cytotoxicity against human HCT-116 cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)
|
[PMID: 36370550] |
| HCT-116 | IC50 |
60.83 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HCT-116 cells incubated for 24 hrs in presence of NAC CCK-8 assay
Cytotoxicity against human HCT-116 cells incubated for 24 hrs in presence of NAC CCK-8 assay
|
[PMID: 36370550] |
| HeLa | IC50 |
10.09 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HeLa cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)
Cytotoxicity against human HeLa cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)
|
[PMID: 36370550] |
| HeLa | IC50 |
10.2 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HeLa cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human HeLa cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 36370550] |
| HeLa | IC50 |
16.08 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HeLa cells incubated for 24 hrs CCK-8 assay
Cytotoxicity against human HeLa cells incubated for 24 hrs CCK-8 assay
|
[PMID: 36370550] |
| HeLa | IC50 |
26.13 μM
Compound: 12d; ZC0109
|
Cytotoxicity against IDO1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 45.93 +/- 2.23 nM)
Cytotoxicity against IDO1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 45.93 +/- 2.23 nM)
|
[PMID: 36370550] |
| HeLa | IC50 |
4.86 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HeLa cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)
Cytotoxicity against human HeLa cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)
|
[PMID: 36370550] |
| HeLa | IC50 |
7.2 μM
Compound: 12d; ZC0109
|
Cytotoxicity against TrxR1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 13.79 +/- 2 uM)
Cytotoxicity against TrxR1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 13.79 +/- 2 uM)
|
[PMID: 36370550] |
| HeLa | IC50 |
74.15 μM
Compound: 12d; ZC0109
|
Cytotoxicity against human HeLa cells incubated for 24 hrs in presence of NAC CCK-8 assay
Cytotoxicity against human HeLa cells incubated for 24 hrs in presence of NAC CCK-8 assay
|
[PMID: 36370550] |
In Vitro
ZC0109 (24 h) inhibits cancer cells with IC50s of 3.44 μM (HCT-116), 12.4 μM (CT26), and 10.2 μM (HeLa), respectively[1].
ZC0109 (2.5-10 μM; 24 h) induces ROS accumulation in HCT-116 and HeLa cells[1].
ZC0109 (2.5-10 μM; 24 h) induces apoptosis and G1/S cell cycle arrest in cancer cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT-116 cells and HeLa cells
-
Concentration:2.5 μM, 5 μM, and 10 μM
-
Incubation Time:24 hours
-
Result:Arrested cell cycle at G1/S phase.
In Vivo
ZC0109 (60 mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplanted immunocompetent BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 3037850-79-3
-
Appearance Solid
-
Molecular Weight 591.41
-
Formula C22H20BrFN8O4S
-
Color White to off-white
-
SMILES
O/N=C(C1=NON=C1NCCCC2=NN=C(S2)NC(CC3=CC=C(C=C3)O)=O)\NC4=CC(Br)=C(C=C4)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (84.54 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6909 mL | 8.4544 mL | 16.9087 mL | 42.2719 mL |
| 5 mM | 0.3382 mL | 1.6909 mL | 3.3817 mL | 8.4544 mL | |
| 10 mM | 0.1691 mL | 0.8454 mL | 1.6909 mL | 4.2272 mL | |
| 15 mM | 0.1127 mL | 0.5636 mL | 1.1272 mL | 2.8181 mL | |
| 20 mM | 0.0845 mL | 0.4227 mL | 0.8454 mL | 2.1136 mL | |
| 25 mM | 0.0676 mL | 0.3382 mL | 0.6763 mL | 1.6909 mL | |
| 30 mM | 0.0564 mL | 0.2818 mL | 0.5636 mL | 1.4091 mL | |
| 40 mM | 0.0423 mL | 0.2114 mL | 0.4227 mL | 1.0568 mL | |
| 50 mM | 0.0338 mL | 0.1691 mL | 0.3382 mL | 0.8454 mL | |
| 60 mM | 0.0282 mL | 0.1409 mL | 0.2818 mL | 0.7045 mL | |
| 80 mM | 0.0211 mL | 0.1057 mL | 0.2114 mL | 0.5284 mL |